“Consolidating these products under one umbrella along with the brilliant minds that can interpret the data will enable higher levels of service to meet our customers’ needs,” said Glenn Bilawsky, i3 CEO. “By combining rich data with leading science, i3 will enable customers to better understand the real-world benefits and risks of their products and gain the most comprehensive understanding of the physicians and patients who use them.”
At the heart of i3 Pharma Informatics lies one of the world’s largest health care databases —currently over 30 terabytes of de-identified information on patient and provider health care experiences. This underlying data asset will continue to grow significantly in 2008 in overall size and depth as more information is aggregated and linked.
Such comprehensive data has been the sole domain of scientists for market research, health economics or outcomes studies, regulatory review or the identification of safety signals. Existing technology has prevented its availability in a user-friendly format for industry professionals. i3, however, has developed intuitive, proprietary and patented technology to bring its significant data assets into the hands of industry in near real time.
i3 will continue to develop enterprise products and further enable the technology around its robust data assets. Initial products included in the new Pharma Informatics Division are:
i3 InVisionTM for Managed Markets—i3’s product that enables customers to identify real market patterns to more precisely, efficiently and effectively position products. i3 InVision™ Data Mart—i3’s broad patient-level database of de-identified medical and pharmacy claims, lab results, and enrollment data. i3 Aperio—i3’s premier drug safety product that helps researchers identify signals that can clarify a drug’s in-market safety profile in near real time. i3 CRAFT—i3’s Clinical Research Analysis and Feasibility Tool that addresses the challenge facing clinical researchers by providing real-time testing of trial design feasibility and the identification of concentrations of appropriate patients and potential clinical investigators.
About i3 i3, a global Ingenix company, provides integrated scientific strategies and solutions throughout the pharmaceutical product lifecycle. It is composed of i3 Research, a therapeutically specialized contract research organization; i3 Drug Safety, engaged in pharmacovigilance and epidemiology; i3 Pharma Informatics, a data, science and technology provider of market analytics; i3 Statprobe, a leader in comprehensive data services; i3 Pharma Resourcing, a world-class staffing partner; and i3 Innovus, delivering the science and solutions to achieve marketplace success. i3 helps companies gain sharper insights that lead to better patient care. For more information, visit www.i3global.com
